JP2019510066A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510066A5 JP2019510066A5 JP2018551358A JP2018551358A JP2019510066A5 JP 2019510066 A5 JP2019510066 A5 JP 2019510066A5 JP 2018551358 A JP2018551358 A JP 2018551358A JP 2018551358 A JP2018551358 A JP 2018551358A JP 2019510066 A5 JP2019510066 A5 JP 2019510066A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- cancer
- unsubstituted
- pharmaceutical composition
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 56
- 206010028980 Neoplasm Diseases 0.000 claims description 55
- 201000011510 cancer Diseases 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 46
- 230000035772 mutation Effects 0.000 claims description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims description 37
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 23
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 23
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 18
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 18
- 206010009944 Colon cancer Diseases 0.000 claims description 16
- 201000001441 melanoma Diseases 0.000 claims description 15
- 102000015735 Beta-catenin Human genes 0.000 claims description 14
- 108060000903 Beta-catenin Proteins 0.000 claims description 14
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 14
- -1 aminopurine compound Chemical class 0.000 claims description 14
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 230000003287 optical effect Effects 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 12
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 12
- 206010017758 gastric cancer Diseases 0.000 claims description 12
- 201000005202 lung cancer Diseases 0.000 claims description 12
- 208000020816 lung neoplasm Diseases 0.000 claims description 12
- 201000011549 stomach cancer Diseases 0.000 claims description 12
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 8
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 8
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 8
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 8
- 201000002528 pancreatic cancer Diseases 0.000 claims description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 8
- 102100039788 GTPase NRas Human genes 0.000 claims description 7
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 7
- 102100038778 Amphiregulin Human genes 0.000 claims description 6
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 6
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 6
- 101000809450 Homo sapiens Amphiregulin Proteins 0.000 claims description 6
- 101000759453 Homo sapiens YY1-associated protein 1 Proteins 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 102100023267 YY1-associated protein 1 Human genes 0.000 claims description 6
- 239000000090 biomarker Substances 0.000 claims description 6
- 206010069755 K-ras gene mutation Diseases 0.000 claims description 5
- 230000037361 pathway Effects 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 101150096411 AXIN2 gene Proteins 0.000 claims description 4
- 102100035683 Axin-2 Human genes 0.000 claims description 4
- 102100021670 Bcl-2-modifying factor Human genes 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 102100031171 CCN family member 1 Human genes 0.000 claims description 4
- 102100031168 CCN family member 2 Human genes 0.000 claims description 4
- 102100033471 Cbp/p300-interacting transactivator 2 Human genes 0.000 claims description 4
- 108010058546 Cyclin D1 Proteins 0.000 claims description 4
- 108010019961 Cysteine-Rich Protein 61 Proteins 0.000 claims description 4
- 101100239628 Danio rerio myca gene Proteins 0.000 claims description 4
- 102100027085 Dual specificity protein phosphatase 4 Human genes 0.000 claims description 4
- 102100027088 Dual specificity protein phosphatase 5 Human genes 0.000 claims description 4
- 102100027274 Dual specificity protein phosphatase 6 Human genes 0.000 claims description 4
- 102100039577 ETS translocation variant 5 Human genes 0.000 claims description 4
- 102100035079 ETS-related transcription factor Elf-3 Human genes 0.000 claims description 4
- 102100023226 Early growth response protein 1 Human genes 0.000 claims description 4
- 108010043945 Ephrin-A1 Proteins 0.000 claims description 4
- 102000020086 Ephrin-A1 Human genes 0.000 claims description 4
- 102000003817 Fos-related antigen 1 Human genes 0.000 claims description 4
- 108090000123 Fos-related antigen 1 Proteins 0.000 claims description 4
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 claims description 4
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims description 4
- 101000896211 Homo sapiens Bcl-2-modifying factor Proteins 0.000 claims description 4
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 claims description 4
- 101000944098 Homo sapiens Cbp/p300-interacting transactivator 2 Proteins 0.000 claims description 4
- 101001057621 Homo sapiens Dual specificity protein phosphatase 4 Proteins 0.000 claims description 4
- 101001057612 Homo sapiens Dual specificity protein phosphatase 5 Proteins 0.000 claims description 4
- 101001057587 Homo sapiens Dual specificity protein phosphatase 6 Proteins 0.000 claims description 4
- 101000813745 Homo sapiens ETS translocation variant 5 Proteins 0.000 claims description 4
- 101000877379 Homo sapiens ETS-related transcription factor Elf-3 Proteins 0.000 claims description 4
- 101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 claims description 4
- 101001002170 Homo sapiens Glutamine amidotransferase-like class 1 domain-containing protein 3, mitochondrial Proteins 0.000 claims description 4
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims description 4
- 101000861454 Homo sapiens Protein c-Fos Proteins 0.000 claims description 4
- 101000702384 Homo sapiens Protein sprouty homolog 2 Proteins 0.000 claims description 4
- 101000629617 Homo sapiens Protein sprouty homolog 4 Proteins 0.000 claims description 4
- 101000944909 Homo sapiens Ribosomal protein S6 kinase alpha-1 Proteins 0.000 claims description 4
- 101000843556 Homo sapiens Transcription factor HES-1 Proteins 0.000 claims description 4
- 101000962469 Homo sapiens Transcription factor MafF Proteins 0.000 claims description 4
- 108090000320 Hyaluronan Synthases Proteins 0.000 claims description 4
- 102000003918 Hyaluronan Synthases Human genes 0.000 claims description 4
- 108090001007 Interleukin-8 Proteins 0.000 claims description 4
- 102000004890 Interleukin-8 Human genes 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 102100027584 Protein c-Fos Human genes 0.000 claims description 4
- 102100030400 Protein sprouty homolog 2 Human genes 0.000 claims description 4
- 102100026845 Protein sprouty homolog 4 Human genes 0.000 claims description 4
- 102100020949 Putative glutamine amidotransferase-like class 1 domain-containing protein 3B, mitochondrial Human genes 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 102100033536 Ribosomal protein S6 kinase alpha-1 Human genes 0.000 claims description 4
- 208000032383 Soft tissue cancer Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 102100039187 Transcription factor MafF Human genes 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 201000007455 central nervous system cancer Diseases 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 2
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 2
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 claims description 2
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 claims description 2
- 102100021337 Gap junction alpha-1 protein Human genes 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 101000894966 Homo sapiens Gap junction alpha-1 protein Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 206010047741 Vulval cancer Diseases 0.000 claims description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 210000004209 hair Anatomy 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 208000016632 ovarian clear cell cancer Diseases 0.000 claims description 2
- 230000026731 phosphorylation Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 102200055451 rs121913361 Human genes 0.000 claims description 2
- 102200044943 rs121913400 Human genes 0.000 claims description 2
- 102220198036 rs121913400 Human genes 0.000 claims description 2
- 102200044940 rs28931589 Human genes 0.000 claims description 2
- 102220006067 rs587776850 Human genes 0.000 claims description 2
- 238000007390 skin biopsy Methods 0.000 claims description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- 206010025654 Malignant melanoma of sites other than skin Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 208000037964 urogenital cancer Diseases 0.000 claims 1
- 0 CC(CC1)(CCC1[n]1c(N)nc2cnc(N*)nc12)C(N)=O Chemical compound CC(CC1)(CCC1[n]1c(N)nc2cnc(N*)nc12)C(N)=O 0.000 description 9
- 239000000126 substance Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317412P | 2016-04-01 | 2016-04-01 | |
| US62/317,412 | 2016-04-01 | ||
| PCT/US2017/025252 WO2017173206A1 (en) | 2016-04-01 | 2017-03-31 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510066A JP2019510066A (ja) | 2019-04-11 |
| JP2019510066A5 true JP2019510066A5 (enExample) | 2020-05-07 |
| JP7014731B2 JP7014731B2 (ja) | 2022-02-01 |
Family
ID=59959573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551358A Active JP7014731B2 (ja) | 2016-04-01 | 2017-03-31 | 置換アミノプリン化合物、その組成物、及びそれらを用いた治療方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10576085B2 (enExample) |
| EP (1) | EP3436018A4 (enExample) |
| JP (1) | JP7014731B2 (enExample) |
| KR (1) | KR102356433B1 (enExample) |
| CN (1) | CN109069512B (enExample) |
| AU (1) | AU2017241837B2 (enExample) |
| BR (1) | BR112018070163A2 (enExample) |
| CA (1) | CA3018986A1 (enExample) |
| CL (1) | CL2018002787A1 (enExample) |
| EA (1) | EA039392B1 (enExample) |
| IL (1) | IL262007B2 (enExample) |
| MX (1) | MX379513B (enExample) |
| NZ (1) | NZ746554A (enExample) |
| SG (2) | SG11201808388QA (enExample) |
| WO (1) | WO2017173206A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| RS65069B1 (sr) | 2015-11-02 | 2024-02-29 | Blueprint Medicines Corp | Inhibitori ret-a |
| WO2017167953A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| HRP20210847T1 (hr) | 2016-03-31 | 2021-07-23 | Janssen Pharmaceuticals, Inc. | Supstituirani derivati indola kao inhibitori replikacije denga virusa |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| EA201892200A1 (ru) | 2016-04-01 | 2019-03-29 | Янссен Фармасьютикалз, Инк. | Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге |
| MX379439B (es) | 2016-04-01 | 2025-03-10 | Signal Pharm Llc | Formas sólidas de (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1-metilciclohexano-1-carboxamida y métodos para utilizarlas. |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CA3060583C (en) | 2017-05-22 | 2024-06-04 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| CR20190531A (es) | 2017-05-22 | 2020-03-05 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
| MX2020003620A (es) | 2017-10-04 | 2020-10-28 | Celgene Corp | Composiciones y métodos para usar cis-4-[2-{[(3s,4r)-3-fluorooxan- 4-il]amino}-8-(2,4,6-tricloroanilino)-9h-purin-9-il]-1-etilcicloh exano-1-carboxamida. |
| SG11202009681YA (en) | 2018-04-03 | 2020-10-29 | Blueprint Medicines Corp | Ret inhibitor for use in treating cancer having a ret alteration |
| EP3833372A4 (en) * | 2018-08-10 | 2022-06-08 | Blueprint Medicines Corporation | TREATMENT OF EGFR MUTANT CANCER |
| AU2020257207B2 (en) * | 2019-04-16 | 2026-06-04 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| PH12022551160A1 (en) | 2019-11-15 | 2023-09-25 | Janssen Pharmaceuticals Inc | Treatment and prevention of dengue disease |
| CN115279368B (zh) * | 2019-11-20 | 2024-05-24 | 维瓦斯治疗公司 | 杂芳基化合物 |
| WO2021243192A1 (en) | 2020-05-29 | 2021-12-02 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| CR20220666A (es) | 2020-05-29 | 2023-05-05 | Blueprint Medicines Corp | Composiciones farmacéuticas de pralsetinib |
| CN115916747A (zh) * | 2020-07-01 | 2023-04-04 | 四川海思科制药有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
| KR102664454B1 (ko) * | 2021-08-03 | 2024-05-09 | 한국생명공학연구원 | 젬시타빈에 대한 민감성 향상을 위한 신규 표적 및 이의 활용 |
| CN114681456A (zh) * | 2022-02-23 | 2022-07-01 | 中山大学附属第六医院 | Plx3397在结直肠癌的治疗中的用途 |
| EP4703725A1 (en) | 2024-08-29 | 2026-03-04 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Modulators of the mitotic cell cycle in cancer cells and uses thereof for the treatment of cancer |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| FI109088B (fi) | 1997-09-19 | 2002-05-31 | Leiras Oy | Tabletti ja menetelmä sen valmistamiseksi |
| JP2007517052A (ja) * | 2003-12-23 | 2007-06-28 | ノバルティス アクチエンゲゼルシャフト | 二環式ヘテロ環式ｐ−３８キナーゼ阻害剤 |
| US7521446B2 (en) | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7759342B2 (en) | 2005-01-13 | 2010-07-20 | Signal Pharmaceuticals, Llc | Methods of treatment and prevention using haloaryl substituted aminopurines |
| US7723340B2 (en) | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| WO2007030438A2 (en) * | 2005-09-06 | 2007-03-15 | Pharmacopeia, Inc. | Aminopurine derivatives for treating neurodegenerative diseases |
| WO2007062338A2 (en) | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Solid formulations |
| AU2007249194B2 (en) * | 2006-05-12 | 2012-11-22 | Myrexis, Inc. | Therapeutic compounds and their use in cancer |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| NZ576347A (en) | 2006-10-27 | 2011-10-28 | Signal Pharm Llc | Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith |
| DK2279731T3 (da) | 2008-04-23 | 2013-03-18 | Farmasierra Mfg S L | Forbedret farmaceutisk sammensætning, som indeholder ibuprofen og codein |
| WO2011071491A1 (en) | 2009-12-09 | 2011-06-16 | Signal Pharmaceuticals, Llc | Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol |
| US8680076B2 (en) * | 2010-10-25 | 2014-03-25 | Signal Pharmaceuticals, Llc | Methods of treatment, improvement and prevention using haloaryl substituted aminopurines |
| US8603527B2 (en) | 2010-10-25 | 2013-12-10 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations of a substituted diaminopurine |
| US9466042B2 (en) | 2012-01-24 | 2016-10-11 | International Business Machines Corporation | Facilitating the design of information technology solutions |
| WO2014172616A2 (en) | 2013-04-18 | 2014-10-23 | President And Fellows Of Harvard College | Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| DK3204386T3 (da) * | 2014-10-06 | 2021-05-25 | Signal Pharm Llc | Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed |
| CN115131834A (zh) * | 2015-08-13 | 2022-09-30 | 小米科技有限责任公司 | 移动设备及其屏幕模组、指纹采集方法、装置及电子设备 |
| MX379439B (es) * | 2016-04-01 | 2025-03-10 | Signal Pharm Llc | Formas sólidas de (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1-metilciclohexano-1-carboxamida y métodos para utilizarlas. |
-
2017
- 2017-03-31 US US15/475,899 patent/US10576085B2/en active Active
- 2017-03-31 EA EA201892229A patent/EA039392B1/ru unknown
- 2017-03-31 MX MX2018011992A patent/MX379513B/es unknown
- 2017-03-31 KR KR1020187028514A patent/KR102356433B1/ko active Active
- 2017-03-31 CN CN201780021651.0A patent/CN109069512B/zh active Active
- 2017-03-31 WO PCT/US2017/025252 patent/WO2017173206A1/en not_active Ceased
- 2017-03-31 SG SG11201808388QA patent/SG11201808388QA/en unknown
- 2017-03-31 JP JP2018551358A patent/JP7014731B2/ja active Active
- 2017-03-31 EP EP17776735.7A patent/EP3436018A4/en not_active Withdrawn
- 2017-03-31 NZ NZ746554A patent/NZ746554A/en unknown
- 2017-03-31 SG SG10202009589UA patent/SG10202009589UA/en unknown
- 2017-03-31 BR BR112018070163A patent/BR112018070163A2/pt not_active Application Discontinuation
- 2017-03-31 CA CA3018986A patent/CA3018986A1/en not_active Abandoned
- 2017-03-31 AU AU2017241837A patent/AU2017241837B2/en active Active
- 2017-03-31 IL IL262007A patent/IL262007B2/en unknown
-
2018
- 2018-09-28 CL CL2018002787A patent/CL2018002787A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vasan et al. | A view on drug resistance in cancer | |
| Eng et al. | Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas | |
| Krings et al. | Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma | |
| Yaeger et al. | Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients | |
| Castinetti et al. | 15 years of paraganglioma: imaging and imaging-based treatment of pheochromocytoma and paraganglioma | |
| Loaiza-Bonilla et al. | Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine | |
| Macerelli et al. | Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)? | |
| Chan et al. | The landscape of actionable molecular alterations in immunomarker-defined large-cell carcinoma of the lung | |
| Shen et al. | microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation | |
| Lee et al. | A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells though MAPK activation | |
| Derbel et al. | Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery | |
| Sung et al. | FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy | |
| US20210388451A1 (en) | Methods for analysis of cell-free rna | |
| Sarfaty et al. | RET fusion lung carcinoma: response to therapy and clinical features in a case series of 14 patients | |
| JP2018525994A5 (enExample) | ||
| Kotlowska et al. | Efficacy of immunotherapy in sarcomatoid lung cancer, a case report and literature review | |
| TW201805000A (zh) | 利用erk抑制劑之鱗狀細胞癌之治療 | |
| Tabatabaeifar et al. | Use of next generation sequencing in head and neck squamous cell carcinomas: A review | |
| Lee et al. | Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer | |
| HRP20211546T1 (hr) | (1s,4s)-4-(2-(((3s,4r)-3-fluortetrahidro-2h-piran-4-il)amino)-8-((2,4,6-triklorfenil)amino)-9h-purin-9-il)-1 -metilcikloheksan-1 -karboksamid i postupci njegove uporabe | |
| García-Alfonso et al. | Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology | |
| Cascinu et al. | Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors | |
| Konstantinova et al. | Molecular alterations in lesions of anogenital mammary-like glands and their mammary counterparts including hidradenoma papilliferum, intraductal papilloma, fibroadenoma and phyllodes tumor | |
| Bohn et al. | BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation | |
| Morabito et al. | Activity of gefitinib in a non–small-cell lung cancer patient with both activating and resistance EGFR mutations |